August 7, 2026

Consolidated Financial Results for the Fiscal Year Ended June 30, 2026 (Under Japanese GAAP)

Company name: KOA SHOJI HOLDINGS CO.,LTD.
Listing: Tokyo Stock Exchange
Securities code: 9273
URL: https://www.koashoji-hd.com/
Representative: Toshiyuki SHUTO, President and Representative Director
Inquiries: Miyoko KOMATSU, Managing Director in charge of Finance & Accounting
Telephone: +81-45-560-6607

Scheduled date of annual general meeting of shareholders: September 25, 2026
Scheduled date to commence dividend payments: September 28, 2026
Scheduled date to file annual securities report: September 18, 2026
Preparation of supplementary material on financial results: Yes
Holding of financial results briefing: Yes (for analysts and institutional investors)

(Yen amounts are rounded down to millions, unless otherwise noted.)

1. Consolidated financial results for the fiscal year ended June 30, 2026 (from July 1, 2025 to June 30, 2026)

(1) Consolidated operating results

(Percentages indicate year-on-year changes.)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent	
Fiscal year ended	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
June 30, 2026	24,678	6.1	5,476	2.3	5,521	2.7	3,748	3.0
June 30, 2025	23,269	5.1	5,355	22.2	5,375	23.1	3,637	23.5

Note: Comprehensive income For the fiscal year ended June 30, 2026: ¥3,733 million [3.2%]
For the fiscal year ended June 30, 2025: ¥3,616 million [21.7%]

	Basic earnings per share	Diluted earnings per share	Return on equity	Ratio of ordinary profit to total assets	Ratio of operating profit to net sales
Fiscal year ended	Yen	Yen	%	%	%
June 30, 2026	89.00	-	12.6	14.6	22.2
June 30, 2025	86.38	-	13.7	15.8	23.0

Note: "Net income per share adjusted for potential shares" is not included because there are no potential shares.

(2) Consolidated financial position

	Total assets	Net assets	Equity-to-asset ratio	Net assets per share
As of	Millions of yen	Millions of yen	%	Yen
June 30, 2026	39,532	31,180	78.9	740.30
June 30, 2025	36,114	28,120	77.9	667.66

Reference: Equity
As of June 30, 2026: ¥31,180 million
As of June 30, 2025: ¥28,120 million

(3) Consolidated cash flows

	Cash flows from operating activities	Cash flows from investing activities	Cash flows from financing activities	Cash and cash equivalents at end of period
Fiscal year ended	Millions of yen	Millions of yen	Millions of yen	Millions of yen
June 30, 2026	7,592	(8,154)	189	14,388
June 30, 2025	3,777	(1,282)	(938)	14,739

2. Cash dividends

	Annual dividends per share					Total cash dividends (Total)	Payout ratio (Consolidated)	Ratio of dividends to net assets (Consolidated)
	First quarter-end	Second quarter-end	Third quarter-end	Fiscal year-end	Total			
	Yen	Yen	Yen	Yen	Yen	Millions of yen	%	%
Fiscal year ended June 30, 2025	-	0.00	-	16.00	16.00	673	18.5	2.5
Fiscal year ended June 30, 2026	-	0.00	-	18.00	18.00	758	20.2	2.6
Fiscal year ending June 30, 2027 (Forecast)		0.00		19.00	19.00		22.3	

3. Forecast of consolidated financial results for the fiscal year ending June 30, 2027 (from July 1, 2026 to June 30, 2027)

(Percentages indicate year-on-year changes.)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent		Basic earnings per share
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Yen
Fiscal year ending June 30, 2027	26,700	8.2	5,270	(3.8)	5,260	(4.7)	3,590	(4.2)	85.24

***Notes**

(1)Significant changes in the scope of consolidation during the period: None

(2) Changes in accounting policies, changes in accounting estimates, and restatement

(i) Changes in accounting policies due to revisions to accounting standards and other regulations: None

(ii) Changes in accounting policies due to other reasons: None

(iii) Changes in accounting estimates: None

(iv) Restatement: None

(3)Number of issued shares (common shares)

(i) Total number of issued shares at the end of the period (including treasury shares)

As of June 30, 2026	42,119,980 shares
As of June 30, 2025	42,119,980 shares

(ii) Number of treasury shares at the end of the period

As of June 30, 2026	1,476 shares
As of June 30, 2025	1,476 shares

(iii) Average number of shares outstanding during the period

Fiscal year ended June 30, 2026	42,118,504 shares
Fiscal year ended June 30, 2025	42,118,596 shares

* Financial results reports are exempt from audit conducted by certified public accountants or an audit firm.

* Proper use of earnings forecasts, and other special matters

(Cautions on forward-looking statements, etc.)

The forward-looking statements, including forecasts of financial results, contained in these materials are based on information currently available to the Company and on certain assumptions deemed to be reasonable. However, the Company makes no guarantee that these forecasts will be achieved. Actual financial results, etc. may differ substantially due to various factors. For the conditions on which earnings forecasts are predicated and precautions for the use of earnings forecasts, please refer to Appendix P2 "1. Summary of Business Results, etc."

(Method of accessing supplementary material on financial results and contents of the financial results briefing)

The Company plans to hold financial results briefing for analysts and institutional investors on Friday, August 7, 2026.

Supplementary financial results materials will be disclosed on TDnet on the same day and will be posted on the Company's website.

Consolidated balance sheet

(Thousands of yen)

	As of June 30, 2025	As of June 30, 2026
Assets		
Current assets		
Cash and deposits	14,919,028	17,210,460
Notes receivable - trade	19,174	3,322
Accounts receivable - trade	3,555,953	3,402,023
Electronically recorded monetary claims - operating	4,546,823	1,261,314
Securities	-	369,619
Merchandise and finished goods	2,124,094	1,774,863
Work in process	540,924	471,102
Raw materials and supplies	599,763	595,009
Other	221,905	242,151
Total current assets	26,527,666	25,329,867
Non-current assets		
Property, plant and equipment		
Buildings and structures	5,654,060	5,792,615
Accumulated depreciation	(2,748,896)	(2,965,290)
Buildings and structures, net	2,905,164	2,827,324
Machinery, equipment and vehicles	3,870,459	4,053,696
Accumulated depreciation	(2,958,177)	(3,228,356)
Machinery, equipment and vehicles, net	912,281	825,339
Tools, furniture and fixtures	1,530,744	1,605,783
Accumulated depreciation	(1,200,143)	(1,288,177)
Tools, furniture and fixtures, net	330,600	317,605
Land	1,807,189	1,806,426
Construction in progress	3,240,308	6,588,576
Total property, plant and equipment	9,195,544	12,365,272
Intangible assets		
Other	8,661	7,622
Total intangible assets	8,661	7,622
Investments and other assets		
Investment securities	89,928	1,570,913
Deferred tax assets	263,690	235,345
Retirement benefit asset	17,490	9,743
Other	11,776	13,946
Total investments and other assets	382,886	1,829,947
Total non-current assets	9,587,091	14,202,842
Total assets	36,114,758	39,532,710

(Thousands of yen)

	As of June 30, 2025	As of June 30, 2026
Liabilities		
Current liabilities		
Notes and accounts payable - trade	1,567,463	1,291,884
Electronically recorded obligations - operating	448,935	171,910
Accounts payable - other	361,305	299,126
Accounts payable - facilities	1,277,390	1,374,159
Short-term borrowings	860,000	2,080,280
Current portion of long-term borrowings	349,904	269,504
Income taxes payable	1,039,296	896,967
Provision for bonuses	47,964	59,129
Other	411,420	508,528
Total current liabilities	6,363,679	6,951,491
Non-current liabilities		
Long-term borrowings	1,241,480	971,976
Deferred tax liabilities	7,192	6,230
Provision for retirement benefits for directors (and other officers)	162,767	170,750
Retirement benefit liability	146,049	170,160
Other	72,925	81,732
Total non-current liabilities	1,630,414	1,400,849
Total liabilities	7,994,094	8,352,340
Net assets		
Shareholders' equity		
Share capital	1,338,752	1,338,752
Capital surplus	1,022,303	1,022,303
Retained earnings	25,733,458	28,808,307
Treasury shares	(484)	(484)
Total shareholders' equity	28,094,029	31,168,878
Accumulated other comprehensive income		
Valuation difference on available-for-sale securities	30,798	8,916
Deferred gains or losses on hedges	(4,163)	2,574
Total accumulated other comprehensive income	26,634	11,491
Total net assets	28,120,664	31,180,369
Total liabilities and net assets	36,114,758	39,532,710

Consolidated statement of income

(Thousands of yen)

	Fiscal year ended June 30, 2025	Fiscal year ended June 30, 2026
Net sales	23,269,231	24,678,859
Cost of sales	15,571,839	16,674,695
Gross profit	7,697,392	8,004,163
Selling, general and administrative expenses	2,342,210	2,527,991
Operating profit	5,355,182	5,476,171
Non-operating income		
Interest and dividend income	6,249	12,330
Interest on securities	-	26,203
Foreign exchange gains	16,138	-
Commission income	10,272	10,769
Compensation income	35,968	1,181
Subsidy income	-	31,325
Other	8,247	18,726
Total non-operating income	76,875	100,536
Non-operating expenses		
Interest expenses	15,133	22,960
Foreign exchange losses	-	22,379
Loss on cancellation of leases	5,777	-
Loss on retirement of non-current assets	7,117	131
Compensation expenses	26,235	-
Other	2,045	9,457
Total non-operating expenses	56,310	54,927
Ordinary profit	5,375,748	5,521,781
Extraordinary income		
Gain on sale of non-current assets	-	3,552
Total extraordinary income	-	3,552
Extraordinary losses		
Loss on sale of non-current assets	4,506	-
Total extraordinary losses	4,506	-
Profit before income taxes	5,371,241	5,525,333
Income taxes - current	1,737,152	1,742,704
Income taxes - deferred	(3,907)	33,884
Total income taxes	1,733,244	1,776,588
Profit	3,637,996	3,748,744
Profit attributable to owners of parent	3,637,996	3,748,744

Consolidated statement of comprehensive income

(Thousands of yen)

	Fiscal year ended June 30, 2025	Fiscal year ended June 30, 2026
Profit	3,637,996	3,748,744
Other comprehensive income		
Valuation difference on available-for-sale securities	(10,671)	(21,882)
Deferred gains or losses on hedges	(10,716)	6,738
Total other comprehensive income	(21,387)	(15,143)
Comprehensive income	3,616,609	3,733,601
Comprehensive income attributable to		
Comprehensive income attributable to owners of parent	3,616,609	3,733,601

Consolidated statement of changes in equity

Fiscal year ended June 30, 2025

	Shareholders' equity					Accumulated other comprehensive income			Total net assets
	Share capital	Capital surplus	Retained earnings	Treasury shares	Total shareholders' equity	Valuation difference on available-for-sale securities	Deferred gains or losses on hedges	Total accumulated other comprehensive income	
Balance at beginning of period	1,338,752	1,022,303	22,643,004	(407)	25,003,652	41,470	6,552	48,022	25,051,674
Changes during period									
Issuance of new shares	-	-	-	-	-	-	-	-	-
Dividends of surplus	-	-	(547,542)	-	(547,542)	-	-	-	(547,542)
Profit attributable to owners of parent	-	-	3,637,996	-	3,637,996	-	-	-	3,637,996
Purchase of treasury shares	-	-	-	(77)	(77)	-	-	-	(77)
Net changes in items other than shareholders' equity	-	-	-	-	-	(10,671)	(10,716)	(21,387)	(21,387)
Total changes during period	-	-	3,090,454	(77)	3,090,377	(10,671)	(10,716)	(21,387)	3,068,989
Balance at end of period	1,338,752	1,022,303	25,733,458	(484)	28,094,029	30,798	(4,163)	26,634	28,120,664

Consolidated statement of changes in equity

Fiscal year ended June 30, 2026

	Shareholders' equity					Accumulated other comprehensive income			Total net assets
	Share capital	Capital surplus	Retained earnings	Treasury shares	Total shareholders' equity	Valuation difference on available-for-sale securities	Deferred gains or losses on hedges	Total accumulated other comprehensive income	
Balance at beginning of period	1,338,752	1,022,303	25,733,458	(484)	28,094,029	30,798	(4,163)	26,634	28,120,664
Changes during period									
Issuance of new shares	-	-	-	-	-	-	-	-	-
Dividends of surplus	-	-	(673,896)	-	(673,896)	-	-	-	(673,896)
Profit attributable to owners of parent	-	-	3,748,744	-	3,748,744	-	-	-	3,748,744
Purchase of treasury shares	-	-	-	-	-	-	-	-	-
Net changes in items other than shareholders' equity	-	-	-	-	-	(21,882)	6,738	(15,143)	(15,143)
Total changes during period	-	-	3,074,848	-	3,074,848	(21,882)	6,738	(15,143)	3,059,705
Balance at end of period	1,338,752	1,022,303	28,808,307	(484)	31,168,878	8,916	2,574	11,491	31,180,369

Consolidated statement of cash flows

(Thousands of yen)

	Fiscal year ended June 30, 2025	Fiscal year ended June 30, 2026
Cash flows from operating activities		
Profit before income taxes	5,371,241	5,525,333
Depreciation	691,734	614,509
Increase (decrease) in provision for bonuses	1,287	11,164
Increase (decrease) in provision for retirement benefits for directors (and other officers)	11,629	7,983
Decrease (increase) in retirement benefit asset	5,678	7,747
Increase (decrease) in retirement benefit liability	(6,508)	24,110
Interest and dividend income	(6,249)	(12,330)
Interest expenses	15,133	22,960
Interest income on securities	-	(26,203)
Compensation income	(35,968)	(1,181)
Subsidy income	(1,057)	(5,000)
Subsidy income	-	(31,325)
Foreign exchange losses (gains)	11,687	(22,379)
Loss (gain) on sale and retirement of non-current assets	11,374	(4,563)
Decrease (increase) in trade receivables	282,594	3,455,290
Decrease (increase) in inventories	(998,468)	429,890
Increase (decrease) in trade payables	(189,013)	(552,603)
Decrease (increase) in accounts receivable - other	(31,704)	(65,958)
Other, net	56,142	84,240
Subtotal	5,189,533	9,461,683
Interest and dividends received	8,490	14,337
Interest paid	(15,824)	(19,861)
Income taxes paid	(1,441,928)	(1,880,414)
Income taxes refund	3	5,235
Proceeds from compensation	35,968	979
Subsidies received	-	31,325
Subsidies received	1,057	5,000
Payments for compensation	-	(26,235)
Net cash provided by (used in) operating activities	3,777,301	7,592,049

(Thousands of yen)

	Fiscal year ended June 30, 2025	Fiscal year ended June 30, 2026
Cash flows from investing activities		
Purchase of investment securities	(3,533)	(1,856,081)
Purchase of non-current assets	(1,888,472)	(3,676,929)
Proceeds from sale of non-current assets	34,064	20,982
Payments into time deposits	(2,816,026)	(5,655,967)
Proceeds from withdrawal of time deposits	3,396,026	3,013,980
Other, net	(4,863)	(50)
Net cash provided by (used in) investing activities	(1,282,805)	(8,154,067)
Cash flows from financing activities		
Repayments of long-term borrowings	(373,904)	(349,904)
Net increase (decrease) in short-term borrowings	-	1,220,280
Dividends paid	(547,361)	(673,211)
Purchase of treasury shares	(77)	-
Other, net	(17,324)	(8,082)
Net cash provided by (used in) financing activities	(938,666)	189,082
Effect of exchange rate change on cash and cash equivalents	(11,687)	22,379
Net increase (decrease) in cash and cash equivalents	1,544,141	(350,555)
Cash and cash equivalents at beginning of period	13,195,373	14,739,515
Cash and cash equivalents at end of period	14,739,515	14,388,960

(Notes on segment information, etc.)

Segment Information

1. Overview of Reporting Segments

The Group's reporting segments are those of the Company's constituent units for which segregated financial information is available and are subject to periodic review by the Board of Directors in order to determine the allocation of management resources and evaluate business performance.

The Group, centered on the Company, which is a pure holding company, has two reporting segments: "API Sales Business" and "Pharmaceutical Manufacturing and Sales Business."

2. Method of calculating the amount of sales, profits or losses, assets and other items for each reporting segment

The method of accounting for the reported business segments is generally the same as described in the "Fundamental Important Matters for the Preparation of Consolidated Financial Statements".

Profit in the reporting segment is a figure based on operating income.

Internal revenues and transfers between reported segments are based on prevailing market prices.

3. Information on the amount of sales, profits or losses, assets and other items for each reported segment, and information on the breakdown of earnings

The previous fiscal year (July 1, 2024 to June 30, 2025)

(Thousands of yen)

	Reportable segments			Adjustment amount (Note 1)	Amount recorded in consolidated financial statements (Note 2)
	API Sales Business	Manufacture and Sales of Pharmaceuticals Business	Total		
Sales					
Revenue generated from customer contracts	14,600,557	8,668,673	23,269,231	-	23,269,231
Other Earnings	-	-	-	-	-
Revenues from external customers	14,600,557	8,668,673	23,269,231	-	23,269,231
Transactions with other segments	1,330,191	-	1,330,191	(1,330,191)	-
Total	15,930,748	8,668,673	24,599,422	(1,330,191)	23,269,231
Segment Profit	3,215,004	2,136,914	5,351,919	3,263	5,355,182
Segment Assets	19,509,945	15,374,075	34,884,021	1,230,737	36,114,758
Other items					
Depreciation	112,874	576,313	689,187	2,547	691,734
Increase in property, plant and equipment and intangible assets	70,733	3,004,601	3,075,335	1,668	3,077,004

Note: 1. The amount of adjustment is as follows.

(1) The adjustment amount of 3,263 thousand yen in segment profit is the elimination of inter-segment transactions and company-wide expenses.

(2) The adjusted amount of 1,230,737 thousand yen for segment assets is the elimination of inter-segment transactions and company-wide assets.

(3) The adjustment for depreciation and amortization of 2,547 thousand yen is the depreciation of assets related to the Company's administrative divisions that are not attributable to the reporting segment.

(4) The adjustment amount of 1,668 thousand yen for the increase in property, plant and equipment and intangible assets is the amount of capital expenditure in the Company's administrative division, which is not attributable to the reporting segment.

2. The total amount of segment profit is in line with the operating profit in the consolidated financial statements.

The current fiscal year (July 1, 2025 to June 30, 2026)

(Thousands of yen)

	Reportable segments			Adjustment amount (Note 1)	Amount recorded in consolidated financial statements (Note 2)
	API Sales Business	Manufacture and Sales of Pharmaceuticals Business	Total		
Sales					
Revenue generated from customer contracts	15,717,087	8,961,772	24,678,859	-	24,678,859
Other Earnings	-	-	-	-	-
Revenues from external customers	15,717,087	8,961,772	24,678,859	-	24,678,859
Transactions with other segments	1,241,246	-	1,241,246	(1,241,246)	-
Total	16,958,333	8,961,772	25,920,105	(1,241,246)	24,678,859
Segment Profit	3,312,388	2,123,924	5,436,312	39,859	5,476,171
Segment Assets	20,838,906	18,147,075	38,985,982	546,727	39,532,710
Other items					
Depreciation	106,608	506,910	613,518	990	614,509
Increase in property, plant and equipment and intangible assets	101,626	3,681,722	3,783,349	1,106	3,784,455

Note: 1. The amount of adjustment is as follows.

(1) The adjustment amount of 39,859 thousand yen in segment profit is the elimination of inter-segment transactions and company-wide expenses.

(2) The adjusted amount of 546,727 thousand yen for segment assets is the elimination of inter-segment transactions and company-wide assets.

(3) The depreciation and amortization adjustment of 990 thousand yen is the depreciation of assets related to the Company's administrative divisions that are not attributable to the reporting segment.

(4) The adjustment amount of 1,106 thousand yen for the increase in property, plant and equipment and intangible assets is the amount of capital expenditure in the Company's administrative division, which is not attributable to the reporting segment.

2. The total amount of segment profit is in line with the operating profit in the consolidated financial statements.

Related Information

The previous fiscal year (July 1, 2024 to June 30, 2025)

1. Product and Service Information

(Thousands of yen)

	Drug Substance Sales Business	Pharmaceutical Marketing Business	Total
Revenues from external customers	14,600,557	8,668,673	23,269,231

2. Regional Information

(1) Net sales

Since sales to external customers in Japan exceed 90% of sales in the consolidated statements of income, the description is omitted.

(2) Property, plant and equipment

Since there are no property, plant and equipment located outside of Japan, there is no applicable matter.

3. Information per main customer

(Thousands of yen)

Name or surname of the customer	Sales	Relevant Segment Names
Fuso Pharmaceutical Co., Ltd.	5,019,474	Drug substance sales business and pharmaceutical manufacturing and sales business

The current fiscal year (July 1, 2025 to June 30, 2026)

1. Product and Service Information

(Thousands of yen)

	Drug Substance Sales Business	Pharmaceutical Marketing Business	Total
Revenues from external customers	15,717,087	8,961,772	24,678,859

2. Regional Information

(1) Net sales

Since sales to external customers in Japan exceed 90% of sales in the consolidated statements of income, the description is omitted.

(2) Property, plant and equipment

Since there are no property, plant and equipment located outside of Japan, there is no applicable matter.

3. Information per main customer

(Thousands of yen)

Name or surname of the customer	Sales	Relevant Segment Names
Fuso Pharmaceutical Co., Ltd.	5,641,825	Drug substance sales business and pharmaceutical manufacturing and sales business
Towa Pharmaceutical Co., Ltd.	3,003,253	Drug Substance Sales Business

Information on impairment losses on fixed assets by reporting segment

Not applicable.

Information on amortization and unamortized balances of goodwill by reporting segment

Not applicable.

Information on Negative Goodwill Accrual Gains by Reporting Segment

Not applicable.